Dae-Won Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dae-Won Kim has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Jeong-Min Oh
Clinical Research Institute, Daejeon St. Mary’s Hospital, Daejeon, Republic of Korea
2 shared publications Jongbum Kwon
Department of Thoracic and Cardiovascular Surgery, Daejeon St. Mary’s Hospital The Catholic University of Korea Seoul Republic of Korea
2 shared publicationsKiyuk Chang
Department of Internal Medicine Division of Cardiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea Seoul Republic of Korea
2 shared publicationsKyusup Lee
Division of Cardiology, Department of Internal Medicine, Daejeon St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
2 shared publications- Kyusup Lee
Department of Cardiology, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 34943, Republic of Korea
2 shared publications Mahn-Won Park
Division of Cardiology, Department of Internal Medicine, Daejeon St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Clinical Impact of Adherence to Fractional Flow Reserve Guidance in Acute Coronary Syndrome
Background: Fractional flow reserve (FFR) is established to guide revascularization in stable coronary disease and non‐culprit lesions in acute coronary syndromes (ACS). However, real‐world adherence to FFR guidance across the spectrum of ACS presentations, including ambiguous culprit scenarios, remains incompletely characterized. Aims: To evaluate the clinical impact of adherence to FFR guidance in ACS. Methods: From a multicenter prospective FFR registry, we analyzed 501 ACS patients who underwent FFR measurement: 222 with clear culprit lesions and 279 with ambiguous culprit lesions. Patients were classified as FFR‐concordant (all FFR ≤ 0.80 treated; all FFR > 0.80 deferred) or FFR‐discordant (≥ 1 FFR‐hemodynamic mismatch). The patient‐oriented composite endpoint (POCE) comprised all‐cause death, myocardial infarction, or any revascularization; the patient‐oriented FFR‐related composite endpoint (POFRC) comprised cardiac death or myocardial infarction or revascularization involving an FFR‐assessed vessel at 2 years. Results: Among 501 patients, 431 (86%) received FFR‐concordant management and 70 (14%) FFR‐discordant management. FFR discordance clustered in the gray zone (0.75–0.85), with 3.5‐fold higher prevalence compared with other FFR ranges. Over 2 years, FFR‐discordant management was associated with significantly higher POCE (Kaplan−Meier incidence 20.0% vs. 10.4%; propensity‐weighted hazard ratio [HR] 2.33, 95% confidence interval [CI] 1.27–4.29, p = 0.009). The POFRC confirmed and strengthened this association (19.0% vs. 8.8%; propensity‐weighted HR 2.59, 95% CI 1.37–4.91, p = 0.004). The adverse impact of FFR discordance was consistent across clear culprit and ambiguous culprit subgroups ( p for interaction = 0.52) and across types of ACS ( p for interaction = 0.91). Conclusions: In real‐world ACS management, adherence to FFR guidance is associated with superior clinical outcomes compared with FFR‐discordant decision‐making.
- 11 September 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Open AccessClinical Impact of Adherence to Fractional Flow Reserve Guidance in Acute Coronary Syndrome
Background: Fractional flow reserve (FFR) is established to guide revascularization in stable coronary disease and non‐culprit lesions in acute coronary syndromes (ACS). However, real‐world adherence to FFR guidance across the spectrum of ACS presentations, including ambiguous culprit scenarios, remains incompletely characterized. Aims: To evaluate the clinical impact of adherence to FFR guidance in ACS. Methods: From a multicenter prospective FFR registry, we analyzed 501 ACS patients who underwent FFR measurement: 222 with clear culprit lesions and 279 with ambiguous culprit lesions. Patients were classified as FFR‐concordant (all FFR ≤ 0.80 treated; all FFR > 0.80 deferred) or FFR‐discordant (≥ 1 FFR‐hemodynamic mismatch). The patient‐oriented composite endpoint (POCE) comprised all‐cause death, myocardial infarction, or any revascularization; the patient‐oriented FFR‐related composite endpoint (POFRC) comprised cardiac death or myocardial infarction or revascularization involving an FFR‐assessed vessel at 2 years. Results: Among 501 patients, 431 (86%) received FFR‐concordant management and 70 (14%) FFR‐discordant management. FFR discordance clustered in the gray zone (0.75–0.85), with 3.5‐fold higher prevalence compared with other FFR ranges. Over 2 years, FFR‐discordant management was associated with significantly higher POCE (Kaplan−Meier incidence 20.0% vs. 10.4%; propensity‐weighted hazard ratio [HR] 2.33, 95% confidence interval [CI] 1.27–4.29, p = 0.009). The POFRC confirmed and strengthened this association (19.0% vs. 8.8%; propensity‐weighted HR 2.59, 95% CI 1.37–4.91, p = 0.004). The adverse impact of FFR discordance was consistent across clear culprit and ambiguous culprit subgroups ( p for interaction = 0.52) and across types of ACS ( p for interaction = 0.91). Conclusions: In real‐world ACS management, adherence to FFR guidance is associated with superior clinical outcomes compared with FFR‐discordant decision‐making.
- Open Access
- 1 July 2026
- Published by American Vacuum Society in Biointerphases
- Vol. 21 (4)
Enhanced biocompatibility and endothelialization of silk fibroin-derived peptide-based coating for cardiovascular tissue engineering applications
Polycaprolactone (PCL) has emerged as a promising biomaterial for artificial heart applications due to its biodegradability and mechanical properties. However, its hydrophobic nature and limited biocompatibility pose challenges for cardiovascular applications, requiring optimal cell-material interactions. This study investigates the surface modification of silk fibroin-derived peptide/PCL coatings to enhance biocompatibility and cellular response for potential artificial heart applications. PCL substrates were blended with varying concentrations of silk fibroin-derived peptide (0.2%, 0.5%, and 1% w/v). Surface characterization was performed using water contact angle measurements, Fourier transform infrared spectroscopy (FTIR), and scanning electron microscopy. Biocompatibility was evaluated through cell viability assays and CD31 expression analysis. Silk fibroin-derived peptide incorporation significantly improved surface hydrophilicity, with contact angles decreasing from 78° (bare PCL) to 62° (1% silk fibroin-derived peptide). FTIR analysis confirmed successful incorporation of silk fibroin-derived peptides, showing characteristic PCL ester C=O absorption at ∼1720 cm−1 and concentration-dependent amide I contributions at ∼1630–1670 cm−1. Cell viability studies demonstrated enhanced cellular response with increasing silk fibroin-derived peptide concentration, particularly evident at day 7. CD31 expression analysis revealed improved endothelial marker expression, with the highest levels observed on 1% silk fibroin-derived peptide-incorporated substrates. The results demonstrate that silk fibroin blended to PCL significantly enhances biocompatibility through improved hydrophilicity and cellular interactions. Taken together, these preliminary results indicate that silk fibroin-derived peptide-incorporated PCL could represent a promising biomaterial platform for artificial heart applications, with the potential to improve endothelial compatibility and support endothelialization.
- 1 July 2026
- Published by American Vacuum Society in Biointerphases
- Vol. 21 (4)
Open AccessEnhanced biocompatibility and endothelialization of silk fibroin-derived peptide-based coating for cardiovascular tissue engineering applications
Polycaprolactone (PCL) has emerged as a promising biomaterial for artificial heart applications due to its biodegradability and mechanical properties. However, its hydrophobic nature and limited biocompatibility pose challenges for cardiovascular applications, requiring optimal cell-material interactions. This study investigates the surface modification of silk fibroin-derived peptide/PCL coatings to enhance biocompatibility and cellular response for potential artificial heart applications. PCL substrates were blended with varying concentrations of silk fibroin-derived peptide (0.2%, 0.5%, and 1% w/v). Surface characterization was performed using water contact angle measurements, Fourier transform infrared spectroscopy (FTIR), and scanning electron microscopy. Biocompatibility was evaluated through cell viability assays and CD31 expression analysis. Silk fibroin-derived peptide incorporation significantly improved surface hydrophilicity, with contact angles decreasing from 78° (bare PCL) to 62° (1% silk fibroin-derived peptide). FTIR analysis confirmed successful incorporation of silk fibroin-derived peptides, showing characteristic PCL ester C=O absorption at ∼1720 cm−1 and concentration-dependent amide I contributions at ∼1630–1670 cm−1. Cell viability studies demonstrated enhanced cellular response with increasing silk fibroin-derived peptide concentration, particularly evident at day 7. CD31 expression analysis revealed improved endothelial marker expression, with the highest levels observed on 1% silk fibroin-derived peptide-incorporated substrates. The results demonstrate that silk fibroin blended to PCL significantly enhances biocompatibility through improved hydrophilicity and cellular interactions. Taken together, these preliminary results indicate that silk fibroin-derived peptide-incorporated PCL could represent a promising biomaterial platform for artificial heart applications, with the potential to improve endothelial compatibility and support endothelialization.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 5 (4) , 380
Preclinical Feasibility and Structural Optimization of a 3D-Printed Silicone-Based Pulmonary Valve Prosthesis: An In Vitro Evaluation
- 1 January 2026
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 5 (4) , 380
Open AccessPreclinical Feasibility and Structural Optimization of a 3D-Printed Silicone-Based Pulmonary Valve Prosthesis: An In Vitro Evaluation
- Open Access
- 1 August 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (15) , e028976
Comparative Effectiveness of Long‐Term Maintenance Beta‐Blocker Therapy After Acute Myocardial Infarction in Stable, Optimally Treated Patients Undergoing Percutaneous Coronary Intervention
Background: The benefits of long‐term maintenance beta‐blocker (BB) therapy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) have not been well established. Methods and Results: Using the Korean nationwide registry, a total of 7159 patients with AMI treated with PCI who received BBs at discharge and were free from death or cardiovascular events for 3 months after PCI were included in the analysis. Patients were divided into 4 groups according to BB maintenance duration: 36 months, was associated with better clinical outcomes. These findings might imply that a better prognosis can be expected if patients with AMI maintain BB therapy for ≥36 months after PCI. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02806102.
- 1 August 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (15) , e028976
Open AccessComparative Effectiveness of Long‐Term Maintenance Beta‐Blocker Therapy After Acute Myocardial Infarction in Stable, Optimally Treated Patients Undergoing Percutaneous Coronary Intervention
Background: The benefits of long‐term maintenance beta‐blocker (BB) therapy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) have not been well established. Methods and Results: Using the Korean nationwide registry, a total of 7159 patients with AMI treated with PCI who received BBs at discharge and were free from death or cardiovascular events for 3 months after PCI were included in the analysis. Patients were divided into 4 groups according to BB maintenance duration: 36 months, was associated with better clinical outcomes. These findings might imply that a better prognosis can be expected if patients with AMI maintain BB therapy for ≥36 months after PCI. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02806102.
- Open Access
- 2 June 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (6) , e0286670
Trends and outcome of statin therapy in dialysis patients with atherosclerotic cardiovascular diseases: A population-based cohort study
Background: Although statins are an effective strategy for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in the general population, the benefits for dialysis patients are controversial. We sought to assess trends of statin use and evaluate outcomes of statin therapy in dialysis patients with different types of ASCVD. Methods: This nationwide retrospective population-based cohort study using data from the Korean National Health Insurance Service included adult patients (aged ≥ 18 years) undergoing chronic dialysis who had an initial ASCVD event in the time period of 2013 to 2018. Annual trends of statin use according to age, sex, and ASCVD types were analyzed. The association between 1-year mortality and statin use was examined using multivariable Cox proportional hazards regression analyses. Results: Among 17,242 subjects, 9,611(55.7%) patients were statin users. The overall prevalence of statin use increased from 52.9% in 2013 to 57.7% in 2018; the majority (77%) of dialysis patients were prescribed moderate-intensity statins. The proportions of low- or moderate-intensity statin use were similar, but high-intensity statin use increased from 5.7% in 2013 to 10.5% in 2018. The use of the statin/ezetimibe combination has gradually increased since 2016. Statin use was independently associated with the reduced 1-year all-cause mortality after adjusting for confounding factors (hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.80–0.96, P = 0.004). Conclusion: The prevalence of statin prescriptions in dialysis patients after ASCVD event increased from 2013 to 2018. Most patients received moderate-intensity statin. However, high-intensity statin and statin/ezetimibe combination therapy has remarkably increased. Statin use was associated with decreased 1-year all-cause mortality in dialysis patients with ASCVD.
- 2 June 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (6) , e0286670
Open AccessTrends and outcome of statin therapy in dialysis patients with atherosclerotic cardiovascular diseases: A population-based cohort study
Background: Although statins are an effective strategy for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in the general population, the benefits for dialysis patients are controversial. We sought to assess trends of statin use and evaluate outcomes of statin therapy in dialysis patients with different types of ASCVD. Methods: This nationwide retrospective population-based cohort study using data from the Korean National Health Insurance Service included adult patients (aged ≥ 18 years) undergoing chronic dialysis who had an initial ASCVD event in the time period of 2013 to 2018. Annual trends of statin use according to age, sex, and ASCVD types were analyzed. The association between 1-year mortality and statin use was examined using multivariable Cox proportional hazards regression analyses. Results: Among 17,242 subjects, 9,611(55.7%) patients were statin users. The overall prevalence of statin use increased from 52.9% in 2013 to 57.7% in 2018; the majority (77%) of dialysis patients were prescribed moderate-intensity statins. The proportions of low- or moderate-intensity statin use were similar, but high-intensity statin use increased from 5.7% in 2013 to 10.5% in 2018. The use of the statin/ezetimibe combination has gradually increased since 2016. Statin use was independently associated with the reduced 1-year all-cause mortality after adjusting for confounding factors (hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.80–0.96, P = 0.004). Conclusion: The prevalence of statin prescriptions in dialysis patients after ASCVD event increased from 2013 to 2018. Most patients received moderate-intensity statin. However, high-intensity statin and statin/ezetimibe combination therapy has remarkably increased. Statin use was associated with decreased 1-year all-cause mortality in dialysis patients with ASCVD.
- 16 May 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (10) , e024370
Evidence‐Based Optimal Medical Therapy and Mortality in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention
Background: The secondary prevention with pharmacologic therapy is essential for preventing recurrent cardiovascular events in patients experiencing acute myocardial infarction. Guideline‐based optimal medical therapy (OMT) for patients with acute myocardial infarction consists of antiplatelet therapy, angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers, β‐blockers, and statins. We aimed to determine the prescription rate of OMT use at discharge and to evaluate the impact of OMT on long‐term clinical outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention in the drug‐eluting stent era using nationwide cohort data. Methods and Results: Using the National Health Insurance claims data in South Korea, patients with acute myocardial infarction who had undergone percutaneous coronary intervention with a drug‐eluting stent between July 2013 and June 2017 were enrolled. A total of 35 972 patients were classified into the OMT and non‐OMT groups according to the post–percutaneous coronary intervention discharge medication. The primary end point was all‐cause death, and the 2 groups were compared using a propensity‐score matching analysis. Fifty‐seven percent of patients were prescribed OMT at discharge. During the follow‐up period (median, 2.0 years [interquartile range, 1.1–3.2 years]), OMT was associated with a significant reduction in the all‐cause mortality (adjusted hazard ratio [aHR], 0.82 [95% CI, 0.76–0.90]; P P <0.001). Conclusions: OMT was prescribed at suboptimal rates in South Korea. However, our nationwide cohort study showed that OMT has a benefit for long‐term clinical outcomes on all‐cause mortality and composite outcome of death or coronary revascularization after percutaneous coronary intervention in the drug‐eluting stent era.
- 16 May 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (10) , e024370
Evidence‐Based Optimal Medical Therapy and Mortality in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention
Background: The secondary prevention with pharmacologic therapy is essential for preventing recurrent cardiovascular events in patients experiencing acute myocardial infarction. Guideline‐based optimal medical therapy (OMT) for patients with acute myocardial infarction consists of antiplatelet therapy, angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers, β‐blockers, and statins. We aimed to determine the prescription rate of OMT use at discharge and to evaluate the impact of OMT on long‐term clinical outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention in the drug‐eluting stent era using nationwide cohort data. Methods and Results: Using the National Health Insurance claims data in South Korea, patients with acute myocardial infarction who had undergone percutaneous coronary intervention with a drug‐eluting stent between July 2013 and June 2017 were enrolled. A total of 35 972 patients were classified into the OMT and non‐OMT groups according to the post–percutaneous coronary intervention discharge medication. The primary end point was all‐cause death, and the 2 groups were compared using a propensity‐score matching analysis. Fifty‐seven percent of patients were prescribed OMT at discharge. During the follow‐up period (median, 2.0 years [interquartile range, 1.1–3.2 years]), OMT was associated with a significant reduction in the all‐cause mortality (adjusted hazard ratio [aHR], 0.82 [95% CI, 0.76–0.90]; P P <0.001). Conclusions: OMT was prescribed at suboptimal rates in South Korea. However, our nationwide cohort study showed that OMT has a benefit for long‐term clinical outcomes on all‐cause mortality and composite outcome of death or coronary revascularization after percutaneous coronary intervention in the drug‐eluting stent era.
- Open Access
- 13 October 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (10) , e0258525
Multivessel versus IRA-only PCI in patients with NSTEMI and severe left ventricular systolic dysfunction
Background: A substantial number of patients presenting with non-ST-elevation myocardial infarction (NSTEMI) and multivessel disease (MVD) have severe left ventricular systolic dysfunction (LVSD) (left ventricular ejection fraction (LVEF) less than 35%). But data are lacking regarding optimal percutaneous coronary intervention (PCI) strategy for these patients. The aim of this study was to compare the long-term outcomes of IRA (infarct-related artery)-only and multivessel PCI in patients with NSTEMI and MVD complicated by severe LVSD.Methods: Among 13,104 patients enrolled in the PCI registry from November 2011 to December 2015, patients with NSTEMI and MVD with severe LVSD who underwent successful PCI were screened. The primary outcome was 3-year major adverse cardiovascular events (MACEs), defined as all-cause death, any myocardial infarction, stroke, and any revascularization.Results: Overall, 228 patients were treated with IRA-only PCI (n = 104) or MV-PCI (n = 124). The MACE risk was significantly lower in the MV-PCI group than in the IRA-only PCI group (35.5% vs. 54.8%; hazard ratio [HR] 0.561; 95% confidence interval [CI] 0.378–0.832; p = 0.04). This result was mainly driven by a significantly lower risk of all-cause death (23.4% vs. 41.4%; hazard ratio [HR] 0.503; 95% confidence interval [CI] 0.314–0.806; p = 0.004). The results were consistent after multivariate regression, propensity-score matching, and inverse probability weighting to adjust for baseline differences.Conclusions: Among patients with NSTEMI and MVD complicated with severe LVSD, multivessel PCI was associated with a significantly lower MACE risk. The findings may provide valuable information to physicians who are involved in decision-making for these patients.
- 13 October 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (10) , e0258525
Open AccessMultivessel versus IRA-only PCI in patients with NSTEMI and severe left ventricular systolic dysfunction
Background: A substantial number of patients presenting with non-ST-elevation myocardial infarction (NSTEMI) and multivessel disease (MVD) have severe left ventricular systolic dysfunction (LVSD) (left ventricular ejection fraction (LVEF) less than 35%). But data are lacking regarding optimal percutaneous coronary intervention (PCI) strategy for these patients. The aim of this study was to compare the long-term outcomes of IRA (infarct-related artery)-only and multivessel PCI in patients with NSTEMI and MVD complicated by severe LVSD.Methods: Among 13,104 patients enrolled in the PCI registry from November 2011 to December 2015, patients with NSTEMI and MVD with severe LVSD who underwent successful PCI were screened. The primary outcome was 3-year major adverse cardiovascular events (MACEs), defined as all-cause death, any myocardial infarction, stroke, and any revascularization.Results: Overall, 228 patients were treated with IRA-only PCI (n = 104) or MV-PCI (n = 124). The MACE risk was significantly lower in the MV-PCI group than in the IRA-only PCI group (35.5% vs. 54.8%; hazard ratio [HR] 0.561; 95% confidence interval [CI] 0.378–0.832; p = 0.04). This result was mainly driven by a significantly lower risk of all-cause death (23.4% vs. 41.4%; hazard ratio [HR] 0.503; 95% confidence interval [CI] 0.314–0.806; p = 0.004). The results were consistent after multivariate regression, propensity-score matching, and inverse probability weighting to adjust for baseline differences.Conclusions: Among patients with NSTEMI and MVD complicated with severe LVSD, multivessel PCI was associated with a significantly lower MACE risk. The findings may provide valuable information to physicians who are involved in decision-making for these patients.